Skip to content

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17012829
Enrollment
Unknown
Registered
2017-09-28
Start date
2017-08-29
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematopoietic and lymphoid malignancies

Interventions

Sponsors

Hebei Yanda Ludaopei Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Be diagnosed a kind of Relapsed or Refractory Haematopoietic and Lymphoid Malignancies: 2) ECOG score=2; 3) To be aged 1 to 70 years; 4) More than a month lifetime from the consent signing date.

Exclusion criteria

Exclusion criteria: 1) Serious cardiac insufficiency, left ventricular ejection fraction<50; 2) Has a history of severe pulmonary function damaging; 3) Merging other progressing malignant tumor; 4) Merging uncontrolled infection; 5) Merging the metabolic diseases (except diabetes); 6) Merging severe autoimmune diseases or immunodeficiency disease; 7) Patients with active hepatitis B or hepatitis C; 8) Patients with HIV infection; 9) Has a history of serious allergies on Biological products (including antibiotics); 10) Has acute GvHD on allogeneic hematopoietic stem cell transplantation patients after stopping immunosuppressants a month; 11) Pregnancy or lactation women; 12) Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.

Design outcomes

Primary

MeasureTime frame
complete remission rate;progression-free survival;overall response rate;

Countries

China

Contacts

Public ContactPeihua Lu

Hebei Yanda Ludaopei Hospital

peihua_lu@126.com+86 18611636172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026